bioAffinity Technologies, Inc. has announced a significant change in its ownership structure, with HRT Financial LP now holding over 10% of the company's common stock. This update, filed on November 19, 2026, is noteworthy as it reflects increasing interest in the company and the broader commercial physical and biological research sector.

Background

bioAffinity Technologies, Inc. operates in the commercial physical and biological research sector, classified under SIC 8731. The company trades on the Nasdaq under the ticker symbols BIAF and BIAFW. As an emerging growth company, bioAffinity focuses on innovative solutions in the field of biological research.

What the Filing Says

The SEC filing indicates that HRT Financial LP became a beneficial owner of more than 10% of bioAffinity's outstanding common stock on September 22, 2026. Following this transaction, HRT Financial LP holds 116,782 shares of common stock directly. The filing also notes that HRT Financial holds 1,183 warrants, each exercisable for 1/450 of a share of common stock, with an exercise price of $3,645.

Impact

This change in ownership may affect various stakeholders, including existing shareholders and potential investors. HRT Financial's significant stake could lead to increased scrutiny of bioAffinity's operations and strategic direction. Additionally, the heightened interest in bioAffinity may influence competitors in the commercial physical and biological research sector, prompting them to evaluate their positions.

What's Next

The filing does not say what happens next.